Abionyx Pharma SA

06/08/2021 | Press release | Distributed by Public on 06/07/2021 23:32

ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study With CER-001, the Bio-HDL for the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury